Xilio Therapeutics XLO
NASDAQ XLO
$8.47 -0.06 (-0.70%)
At close: Nov 11, 2026 · 4:00 PM EST

Xilio Therapeutics (XLO) EV to CFO (2025)

Updated

Xilio Therapeutics' EV to CFO came in at -1.66 for Q1 2025.

Analysis

Xilio Therapeutics (XLO) EV to CFO (2025) Analysis & Trends

Over the trailing twelve months to Mar 31, 2025, Xilio Therapeutics reported EV to CFO of -10.73.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Xilio Therapeutics 167.94 Mn -378.15 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 -1.66
API Access

Xilio Therapeutics EV to CFO API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=XLO&period=max&api_key=YOUR_API_KEY